Journals club - HPV vaccine

Curriculum statement 5. Healthy people: promoting health and preventing disease.

Key trials

  • Cervarix is adjuvanted with aluminium hydroxide with monophosphoryl lipid A (ASO4). This has been used in a hepatitis B vaccine, where it was shown to generate a stronger and longer-lasting immune response than a vaccine containing aluminium hydroxide alone (Cancer Immunol Immunother 2008; 57: 443-51).
  • One study showed 90.4 per cent efficacy against cervical intraepithelial neoplasia 2 and 3 associated with HPV16 or HPV18 (Lancet 2007; 369: 2,161-70).
  • A pilot study achieved a 70.6 per cent uptake for the first dose of vaccine, with a drop of only 2.1 per cent for the second dose (BMJ 2008; 336: 1,056-8).

However, the uptake of the vaccine in this study was highest in girls from affluent, white backgrounds, who have the lowest incidence of cervical cancer.

  • The HPV vaccine does appear to be associated with a greater risk (2.6 per 100,000 doses) of anaphylaxis than other immunisations (CMAJ 2008; 179: 525-33).

Evidence base

  • The Royal College of Obstetricians and Gynaecologists has welcomed the government's implementation of the HPV vaccination programme in teenage girls.
  • The DoH accepted advice from the Joint Committee on Vaccination and Immunisation regarding the HPV vaccine.
  • The introduction of the HPV vaccine into the National Immunisation Programme has been detailed in a CMO publication (see


  • The DoH has chosen Cervarix HPV vaccine for the national immunisation campaign.
  • For optimal protection, the vaccine needs to be given before the onset of sexual activity.
  • The routine vaccination of girls aged 12-13 years of age started in September 2008.
  • The choice of vaccine has been criticised by many experts because it means that the potential for vaccination against genital warts is lost.
  • The DoH has stated it is not cost-effective for boys to be vaccinated.
  • Vaccinated women will still need to have regular cervical smear tests because:
    vaccination will take several years to reduce the incidence of cervical cancer;
    vaccination does not offer protection against all HPV types;
    unvaccinated women will not be protected.

Contributed by Dr Louise Newson, a GP in the West Midlands

HPV points

  • Persistent HPV infection can lead to cervical cancer.
  • HPV infection affects approximately 1 in 5 women.
  • Cervarix is the vaccine of choice for the HPV vaccination programme in the UK.
  • Data on long-term immunity with the vaccine is not yet available.
  • Poor uptake of the vaccine is a concern.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus